Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis

Purpose

Sarcoidosis is a multi-system granulomatous disorder that is triggered and influenced by gene-environment interactions. Although sarcoidosis predominantly affects the lungs in most cases, the clinical disease course is highly variable and any organ can be affected leading to end organ damage despite currently available therapeutics that unfortunately also have numerous and potentially devastating side effects. The environmental triggers of sarcoidosis are unknown but several occupational, environmental and infectious agents have been associated with sarcoidosis in susceptible hosts. Exposure to these triggers result in inflammation, characterized by activation of CD4+ T-cells, cytokine production, subsequent recruitment of other immune cells, and granuloma formation. Although several genetic markers have been associated with sarcoidosis, none fully explain individual susceptibility or clinical course variability, strongly implicating the environment and epigenetics. We have the ability to generate a map of the epigenetic histone modifications in immune cells via Chromatin Immuno-Precipitation coupled with next generation sequencing (ChIP-seq) and a map of transcriptome profiles via RNA-seq. The availability of histone and transcriptional signatures defining T cell activity in sarcoidosis will help identify the specific molecular programs affected by disease processes and can become the basis for future discovery of novel biomarker diagnostics in a clinical setting.

Conditions

  • Sarcoidosis
  • Sarcoidosis, Pulmonary

Eligibility

Eligible Ages
Between 18 Years and 85 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Between the ages of 18 and 85 - Diagnosis of sarcoidosis confirmed by either biopsy or by manifestations consistent with acute sarcoidosis in absence of other known diagnosis. - Have a suspected diagnosis of sarcoidosis and is scheduled to undergo a biopsy procedure to confirm a diagnosis of sarcoidosis. - Able to tolerate and willing to undergo study procedures

Exclusion Criteria

  • Current cigarette smoking or smoking within six months prior to the study - Currently or recently (<6months) on immunosuppressive therapy - Pregnancy - Patient inability to participate in the study, such as undergo venipuncture and or BAL

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Sarcoidosis
  • Other: Observational Study
    Observational study utilizing bronchoscopy, and imaging
Healthy Controls
  • Other: Observational Study
    Observational study utilizing bronchoscopy, and imaging

Recruiting Locations

University of California, San Francisco (Parnassus)
San Francisco, California 94143
Contact:
Victoria Wang, BS
415-476-9225
victoria.wang2@ucsf.edu

More Details

NCT ID
NCT03145922
Status
Recruiting
Sponsor
National Jewish Health

Study Contact

Victoria Wang, BS
4154769225
victoria.wang2@ucsf.edu